---
title: "Pain and Hemodynamics in Peripheral Arterial Disease: Response to Pulsed Electromagnetic Treatment"
nct_id: NCT06252181
overall_status: UNKNOWN
phase: NA
sponsor: Ahram Canadian University
study_type: INTERVENTIONAL
primary_condition: Peripheral Arterial Disease
countries: Egypt
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT06252181.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT06252181"
ct_last_update_post_date: 2024-02-09
last_seen_at: "2026-05-12T07:16:29.085Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Pain and Hemodynamics in Peripheral Arterial Disease: Response to Pulsed Electromagnetic Treatment

**Official Title:** Pain and Hemodynamics in Peripheral Arterial Disease: Response to Pulsed Electromagnetic Treatment in Elderly

**NCT ID:** [NCT06252181](https://clinicaltrials.gov/study/NCT06252181)

## Key Facts

- **Status:** UNKNOWN
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 40
- **Lead Sponsor:** Ahram Canadian University
- **Conditions:** Peripheral Arterial Disease
- **Start Date:** 2022-12-15
- **Completion Date:** 2024-03-10
- **CT.gov Last Update:** 2024-02-09

## Brief Summary

patients with peripheral arterial disease are recommended to perform all exercise forms including elliptical type. electromagnetic treatment addition to exercise may increase benefits of this exercise

## Detailed Description

patients (40 elderly) with peripheral arterial disease who take their medications will be divided to older patients group that receive one hour elliptical exercise (n=20 patients, exercise will be applied 3 times per the week for eight week) and a group (n=20) that receive 3 sessions per weeks of 8-week electromagnetic one-hour therapy and one hour elliptical exercise (exercise will be applied 3 times per the week for eight week)

## Eligibility

- **Minimum age:** 65 Years
- **Maximum age:** 75 Years
- **Sex:** MALE
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* older patients
* peripheral arterial disease patients

Exclusion Criteria:

* cardiac elders
* respiratory elders
* renal elders
```

## Arms

- **group number 1** (EXPERIMENTAL) — group of peripheral arterial disease elderly (n=20) that take their medications and will receive 3 sessions per weeks of 8-week electromagnetic one-hour therapy and one hour elliptical exercise (exercise will be applied 3 times per the week for eight week)
- **group number 2** (ACTIVE_COMPARATOR) — patients (20 elderly) with peripheral arterial disease who take their medications will receive one hour elliptical exercise ( exercise will be applied 3 times per the week for eight week)

## Interventions

- **electromagnetic pulsed therapy** (OTHER) — patients (20 elderly) with peripheral arterial disease who take their medications will receive one hour elliptical exercise ( exercise will be applied 3 times per the week for eight week) and 3 sessions per weeks of 8-week electromagnetic one-hour pulsed therapy
- **elliptical exercise** (OTHER) — patients (20 elderly) with peripheral arterial disease who take their medications will receive one hour elliptical exercise (n=20 patients, exercise will be applied 3 times per the week for eight week)

## Primary Outcomes

- **ankle brachial index** _(time frame: It will be measured after 8 weeks)_ — it is an vascular index used in assessment of peripheral arterial disease progression

## Secondary Outcomes

- **posterior tibial artery diameter** _(time frame: It will be measured after 8 weeks)_
- **claudication pain time** _(time frame: It will be measured after 8 weeks)_
- **claudication pain distance** _(time frame: It will be measured after 8 weeks)_
- **Modified walking impairment questionnaire** _(time frame: It will be measured after 8 weeks)_
- **six minute walking test (pain free distance)** _(time frame: It will be measured after 8 weeks)_
- **six minute walking test (total walked distance)** _(time frame: it will be measured after 8 weeks)_
- **intermittent claudication questionnaire** _(time frame: it will be measured after 8 weeks)_
- **short form 36 health questionnaire** _(time frame: it will be measured after 8 weeks)_
- **Short physical performance battery** _(time frame: it will be measured after 8 weeks)_

## Locations (1)

- Ahram canadian university, Giza, Egypt — _RECRUITING_

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.ahram canadian university|giza||egypt` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT06252181.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT06252181*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*